Investment
Features
FeesSafety
Academy
More
Pluang+

Trastuzumab pamirtecan shows strong efficacy in HER2+ recurrent endometrial cancer with manageable safety.

Company Fundamentals
11 Apr 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

BioNTech and DualityBio announced positive Phase 2 trial results for trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, in patients with HER2-expressing recurrent endometrial cancer. The trial showed a confirmed objective response rate of about 48% and median progression-free survival of 8.1 months, including in patients previously treated with immune checkpoint inhibitors. The treatment demonstrated meaningful antitumor activity across all HER2 expression levels with manageable side effects. A global Phase 3 trial is ongoing, and regulatory filings are planned for 2026, highlighting the drug's potential to address a significant unmet need in this cancer type.

More News (BNTX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App